Zhejiang Huayang Pharmaceutical Co., Ltd. was formed in January 2016 when Zhejiang Huazhou Pharmaceutical Co., Ltd. acquired the former Zhejiang Ruiqing Pharmaceutical Co., Ltd. and renamed it Zhejiang Huayang Pharmaceutical Co., Ltd. Founded in December 1994, it is a limited liability company integrating R&D, production and marketing. Located at No.35 Donghai 5th Avenue, Taizhou Bay Economic and Technological Development Zone, Linhai, Zhejiang, it is about 30 km from downtown Taizhou, 40 km from Taizhou Airport, and 15 km from Taizhou Comprehensive Bonded Zone and Toumen Port. With convenient expressways and high-speed rail nearby, the company has complete facilities on a site of about 120 mu and more than 100 employees. Guided by the philosophy of “People-oriented, quality first, medicine for the people, harmony and prosperity”, it organizes production strictly in accordance with GMP and creates a healthier life with care.

The company has modern GMP-compliant workshops and advanced testing equipment such as HPLC, GC and IR spectrophotometers. Products mainly focus on R&D and production of nervous system, gout, cardiovascular, anti-infective antibiotic and related series.

In May 2009, the company obtained Japan PMDA certification. In June 2024, it passed the US FDA cGMP on-site inspection, laying a foundation for internationally compliant supply of pharmaceutical intermediates and APIs. Main products currently include 10-methoxy iminostilbene, iminostilbene, 4-(1-hydroxy-1-methylethyl)-2-propyl-1H-imidazole-5-carboxylic acid ethyl ester, 3-iodooxetane, methyl 2-fluoroacrylate, N,N'-dinitroso pentamethylene tetramine, related phosphate amine salts and other products, sold in domestic and overseas markets.